Payment overview · 2025
General Payments
$876.42
34 reported records · 13 companies
Healthcare provider profile · identity verified
Michael S Schmidt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · THOMASVILLE, GA · NPI 1669572970
Verified facts
What the public records show
CMS Open Payments records show Michael S Schmidt, M.D. received $876.42 in general payments during 2025 across 34 reported records.
BIOTRONIK NRO, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $225.51 | 25.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $173.48 | 19.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.46 | 14.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.27 | 7.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.15 | 7.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.42 | 4.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.09 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.68 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.26 | 3.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.87 | 2.6% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $19.36 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.06 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.81 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.94 | 31 |
| Travel and Lodging | $173.48 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $220.06 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $173.48 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.27 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.28 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.51 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.42 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.87 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Vesicare Normalized: vesicare |
Drug | Astellas Pharma US Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
136 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 56 |
| Metformin Hcl | Metformin Hcl | 302 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 292 | 73 |
| Losartan Potassium | Losartan Potassium | 253 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 47 |
| Omeprazole | Omeprazole | 204 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 43 |
| Lisinopril | Lisinopril | 174 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 32 |
| Ozempic | Semaglutide | 156 | 20 |
| Gabapentin | Gabapentin | 149 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 34 |
| Trulicity | Dulaglutide | 136 | 17 |
| Potassium Chloride | Potassium Chloride | 124 | 30 |
| Meloxicam | Meloxicam | 115 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 28 |
| Famotidine | Famotidine | 108 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 25 |
| Allopurinol | Allopurinol | 104 | 22 |
| Tramadol Hcl | Tramadol Hcl | 98 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 17 |
| Jardiance | Empagliflozin | 94 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 23 |
| Simvastatin | Simvastatin | 84 | 20 |
| Furosemide | Furosemide | 81 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 26 |
| Alprazolam | Alprazolam | 78 | 11 |
| Montelukast Sodium | Montelukast Sodium | 78 | 21 |
| Glipizide | Glipizide | 75 | 17 |
| Carvedilol | Carvedilol | 74 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Ibuprofen | Ibuprofen | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 24 |
| Glimepiride | Glimepiride | 53 | suppressed |
| Eliquis | Apixaban | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 13 |
| Trazodone Hcl | Trazodone Hcl | 50 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 15 |
| Nifedipine Er | Nifedipine | 47 | 14 |
| Prednisone | Prednisone | 47 | 26 |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Januvia | Sitagliptin Phosphate | 41 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Ondansetron Odt | Ondansetron | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 14 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 18 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $876.42 · 34 records | BIOTRONIK NRO, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, Ozempic, PREVNAR 20, PROCLAIM, Prospera, QUTENZA, Rybelsus, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Vesicare, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error